GenNBio Valuation
Is A072520 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A072520 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate A072520's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A072520's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A072520?
Key metric: As A072520 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is A072520's PS Ratio? | |
|---|---|
| PS Ratio | 10.7x |
| Sales | ₩2.69b |
| Market Cap | ₩28.84b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 17.7x |
| Enterprise Value/EBITDA | -4.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does A072520's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.9x | ||
A299170 WSI | 1.2x | n/a | ₩42.7b |
A032940 Wonik | 0.4x | n/a | ₩62.4b |
A118000 METACARE | 0.9x | n/a | ₩52.7b |
A219750 GTG Wellness | 1.2x | n/a | ₩27.0b |
A072520 GenNBio | 10.7x | n/a | ₩28.8b |
Price-To-Sales vs Peers: A072520 is expensive based on its Price-To-Sales Ratio (10.7x) compared to the peer average (3.6x).
Price to Sales Ratio vs Industry
How does A072520's PS Ratio compare vs other companies in the Asian Healthcare Industry?
| 62 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 62 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: A072520 is expensive based on its Price-To-Sales Ratio (10.7x) compared to the Asian Healthcare industry average (1.6x).
Price to Sales Ratio vs Fair Ratio
What is A072520's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 10.7x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate A072520's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Ray
₩93.3b
RAY Co., Ltd. provides x-ray diagnostic equipment in the dental industry.
A228670
₩6,100.00
7D
-5.7%
1Y
-74.0%
Wonbiogen
₩42.7b
Develops and sells medical equipment in South Korea.
A307280
₩1,210.00
7D
-2.1%
1Y
-22.9%
Access Bio
₩190.7b
Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.
A950130
₩5,710.00
7D
2.5%
1Y
-33.7%